Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00853957 · ClinicalTrials.gov registry record · Phase 4
Efficacy and Safety of Aliskiren Administered in Combination With Amlodipine Versus Amlodipine Alone in African American Patients With Stage 2 Hypertension
A Phase 4 study of Hypertension, sponsored by Novartis.
- Completed
- Registry status
- Phase 4
- Development phase
- 443
- Enrollment target
- 9
- Study locations
NCT00853957 is a Phase 4 study of Hypertension that has completed, run by Novartis. The registered enrollment target is 443 participants, below the 3,506-participant average among 470 other Hypertension trials with a reported enrollment target (87% lower). The trial reports 9 study locations across 7 states.
The verdict
NCT00853957, a Phase 4 study of Hypertension, has completed, sponsored by Novartis.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 443 participants
- Enrollment target
- 9
- Study locations
Study Summary
The purpose of the study is to evaluate the BP-lowering efficacy of the combination of aliskiren and amlodipine, as initial therapy, compared to amlodipine monotherapy in African American patients with Stage II hypertension.
Conditions Studied
Interventions
- DRUG Amlodipine
- DRUG Aliskiren/Amlodipine
Study Locations (9)
Maryland
- Investigative Site - Baltimore
- Investigative Site - Oxon Hill
New York
- Investigative Site - Brooklyn
- Investigative Site - Springfield Gardens
Illinois
- Investigative Site - Chicago
Michigan
- Investigative Site - Detroit
New Jersey
- Investigative Site - Trenton
Pennsylvania
- Investigative Site - Philadelphia
Wisconsin
- Investigative Site - Milwaukeee
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 443 participants |
| Start Date | 2009-02 |
| Est. Completion | 2009-08 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00853957
The ClinicalTrials.gov registry entry for NCT00853957 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 443 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,506-participant average among 470 other Hypertension trials with a reported enrollment target (87% lower). The listed sponsor is Novartis, which has 265 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hypertension appearing as the primary indexed condition, and to 2 interventions - of which Amlodipine is the first listed.
NCT00853957 reports 9 study locations spanning 7 distinct geographic areas - top geographies include Maryland, New York, Illinois.
Frequently Asked Questions
What is clinical trial NCT00853957 about?
NCT00853957 is a clinical study titled "Efficacy and Safety of Aliskiren Administered in Combination With Amlodipine Versus Amlodipine Alone in African American Patients With Stage 2 Hypertension". The purpose of the study is to evaluate the BP-lowering efficacy of the combination of aliskiren and amlodipine, as initial therapy, compared to amlodipine monotherapy in African American patients with Stage II hypertension.
What is the current status of trial NCT00853957?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 443 participants. The study started on 2009-02. Estimated completion is 2009-08.
What conditions does trial NCT00853957 study?
This clinical trial studies the following conditions: Hypertension.
What interventions are being tested in trial NCT00853957?
The interventions under investigation include: Amlodipine (DRUG), Aliskiren/Amlodipine (DRUG).
Who is sponsoring clinical trial NCT00853957?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00853957 being conducted?
This trial has 9 study locations across Illinois, Maryland, Michigan, New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Treatment With Aspirin After Preeclampsia: TAP Trial
RECRUITING · Phase 4
-
Impact GLP-1 Agonists Following Bariatric
RECRUITING · Phase 4
-
Cardiovascular Manifestations of MR Activation in Primary Aldosteronism: Pilot Clinical Study
RECRUITING · Phase 4
-
Bridging the Evidence-to-practice Gap
RECRUITING · Phase 4
-
Mineralocorticoid Receptor, Coronary Microvascular Function, and Cardiac Efficiency in Hypertension
RECRUITING · Phase 4
-
Secondhand Tobacco Smoke and Cardiovascular Disease
RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.